AISAP Cardio vs Tempus ECG-AF
AI Verdict
Choose AISAP Cardio if…
Choose AISAP Cardio if you require rapid, comprehensive cardiac diagnostic assessments and measurements directly at the point of care, especially for the early detection of structural heart disease and heart failure. This AI-powered POCUS software is ideal for clinicians needing immediate, detailed insights into valvular pathologies and ventricular function at the bedside.
View AISAP Cardio →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your focus is on proactively identifying patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation or flutter within the next 12 months. This AI-based algorithm analyzes standard 12-lead ECG recordings to support earlier identification and follow-up for AF risk management.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AISAP Cardio | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Cloud-based | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AISAP CardioAISAP Cardio is designed for point-of-care use, providing rapid, comprehensive cardiac assessments and automated reports at the bedside, empowering clinicians with varying skill levels. Tempus ECG-AF, conversely, is an algorithm that analyzes existing ECG data and explicitly states it lacks a dedicated user interface, suggesting a less direct interactive experience for the end-user.
Clinical Value
AISAP CardioAISAP Cardio offers immediate, comprehensive diagnostic assessments for a wide range of structural heart diseases and heart failure at the point of care, providing quantitative measurements and high sensitivity/specificity for major valve diseases. Tempus ECG-AF provides significant value by predicting future AF risk in a specific demographic, but its application is more targeted and predictive rather than immediate, broad diagnosis.
Pricing & Value
Tempus ECG-AFTempus ECG-AF clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, offering a transparent pathway for financial viability for healthcare providers. AISAP Cardio's pricing is not publicly available, making it challenging to assess its financial value proposition without direct vendor engagement.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness. Tempus ECG-AF explicitly states HIPAA compliance and BAA availability, along with compatibility with major ECG systems. AISAP Cardio, while not explicitly stating BAA in the initial facts, is described as using a secure, HIPAA-compliant and ISO-certified cloud, and is vendor-agnostic with EHR/EMR and PACS integration.
Innovation
Tempus ECG-AFTempus ECG-AF's innovation lies in its pioneering FDA clearance for an AF indication in the category of 'cardiovascular machine learning-based notification software,' enabling the prediction of future AF risk from standard ECGs. While AISAP Cardio is innovative in bringing comprehensive AI-powered interpretation to POCUS at the bedside, Tempus ECG-AF's predictive capability represents a distinct and forward-looking application of AI in a newly recognized regulatory category.
Support & Docs
Tempus ECG-AFTempus ECG-AF provides explicit contact information for its Cardiology Support team, including an email and phone number, indicating clear channels for technical assistance. AISAP Cardio's public information, even after web search, does not readily offer specific support channels or documentation portals, making its support infrastructure less transparent.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AISAP Cardio | Tempus ECG-AF |
|---|---|---|
| Name | AISAP Cardio | Tempus ECG-AF |
| Company | Aisap | Tempus AI, Inc. |
| Description | FDA-cleared, AI-powered point-of-care ultrasound (POCUS) software platform that provides rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Key Functionality | AI-powered interpretation for early cardiac disease detection, comprehensive cardiac ultrasound software package, automated generation of analyses, interpretations, and reports, assessment of valvular pathologies, measurement of Left Ventricle Ejection Fraction (LVEF), measurement of right and left ventricular dimensions, atrial areas, ascending aorta diameter, and IVC diameter. | AI-based algorithm for 12-lead ECG analysis, detects signs associated with new onset Atrial Fibrillation (AF) within 12 months, intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Specialties | Cardiology, Emergency Medicine, Radiology | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring AISAP Cardio and Tempus ECG-AF.